Select Vaccines signs agreement to develop Hep C test

By Melissa Trudinger
Thursday, 25 March, 2004

Select Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.

"It's one in a series of MTAs which will put us in the best possible position to have a rapid test that works with a number of rapid systems in the marketplace," said CEO Dr Martin Soust.

Soust said the agreement would cut at least three months off the timeframe required to develop the point-of-care test, and would allow the company to compare multiple rapid systems concurrently.

The MTA also contains the provision that the supplier company will be able to exercise rights to license or on-license any IP that arises from successful development.

Related News

Novel glycopeptide antibiotic candidate shows promise

Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...

Why a gluten-free diet fails in some coeliac patients

Abnormal immune cells are driving ongoing intestinal inflammation that causes symptoms like...

Giving rotavirus vaccine at birth benefits gut bacteria

Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd